|
NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence free interval (IBCRFI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). |
|
|
Honoraria - Genentech/Roche; Genomic Health |
Consulting or Advisory Role - Celgene; Genomic Health; GlaxoSmithKline; Novartis; Pfizer; Ventana Medical Systems |
Speakers' Bureau - Genentech/Roche; Genomic Health |
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Genomic Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Rutgers Cancer Institute of New Jersey |
Consulting or Advisory Role - Elekta; Vertex |
Research Funding - Elekta |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - 21st Century Oncology |
Consulting or Advisory Role - ImpediMed |
|
|
Leadership - Intrinsic LifeSciences (I) |
Stock and Other Ownership Interests - Abbott Laboratories; GlaxoSmithKline; Intrinsic LifeSciences (I); Johnson & Johnson; Merck; Merganser Biotech (I); Novartis; Pfizer; Silarus Therapeutics (I); Teva; xenon pharma (I) |
Consulting or Advisory Role - InformedDNA; Keryx (I); Merganser Biotech (I); Silarus Therapeutics (I) |
Research Funding - Keryx (I) |
Patents, Royalties, Other Intellectual Property - related to iron metabolism and the anemia of chronic disease (I); Up-to-Date royalties for section editor on survivorship |
Travel, Accommodations, Expenses - Intrinsic LifeSciences (I); Keryx (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
Stock and Other Ownership Interests - eviti; Nanthealth |
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly/ImClone |
Consulting or Advisory Role - eviti |
Research Funding - Abbvie (Inst) |
|
|
Research Funding - Bayer (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Abbvie; Genentech; GHI Pharma |